Medical Xpress
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The findings were presented today at the 2024 European Society for Medical Oncology (ESMO) Congress…
Read More
ESMO: Combination therapy reduced agitated delirium in patients with advanced cancers
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The findings were presented today at the 2024 European Society for Medical